Changes in biochemical and coagulological blood tests in patients with bronchial asthma who underwent COVID-19

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study the dynamics of changes in indicators of biochemical blood analysis and markers of the state of hemostasis and fibrinolysis systems in patients with previously treated bronchial asthma (BA) of moderate severity who had and did not have COVID-19 before and during treatment.

Material and methods. The study included 58 patients who were divided into two groups: 1st (BA/COVID-19; n=29) – patients with BA who had undergone COVID-19; 2st (BA; n=29) – patients with BA who had not undergone COVID-19. Markers of impaired liver function, lipid metabolism, as well as a marker of systemic inflammation, C-reactive protein, were studied. The condition of the plasma, antiserum and fibrinolytic systems was assessed. Laboratory tests were performed before the start of treatment and upon discharge from the hospital.

Results. Before the start of treatment, changes in liver function and lipid metabolism were more often detected in the group of patients with BA/COVID-19. By the end of the follow-up, the proportion of patients with laboratory manifestations of cytolysis and lipid metabolism disorders increased more significantly in the BA/COVID-19 group. At the same time, the number of patients with cholestasis phenomena in the BA group decreased significantly, and in the BA/COVID-19 group increased slightly. Hypercoagulation shift was significantly more often detected in the group of patients with BA/COVID-19 and by the end of the follow-up, the number of such patients increased, and in the BA group their number significantly decreased. Before the start of treatment, systemic inflammation was observed in most patients, by the end of the follow-up, the number of such patients in both groups decreased, but in the BA/COVID-19 group, the proportion of such patients was significantly higher.

Full Text

Restricted Access

About the authors

R. Yu. Abdullaev

Central Research Institute of Tuberculosis

Author for correspondence.
Email: rizvan0403@yandex.ru
ORCID iD: 0000-0002-9105-9264
SPIN-code: 4535-2302

Professor, MD

Russian Federation, Moscow

V. A. Shorokhova

Central Research Institute of Tuberculosis

Email: rizvan0403@yandex.ru
ORCID iD: 0000-0002-7143-3204
SPIN-code: 8154-7188

Candidate of Medical Sciences

Russian Federation, Moscow

O. G. Komissarova

Central Research Institute of Tuberculosis; N.I. Pirogov Russian National Research Medical University

Email: rizvan0403@yandex.ru
ORCID iD: 0000-0003-4427-3804
SPIN-code: 6006-6732

MD

Russian Federation, Moscow; Moscow

References

  1. Клинические рекомендации. Бронхиальная астма. 2021; с. 9–12. [Clinical recommendations. Bronchial asthma. 2021; рр. 9–12 (in Russ.)]. URL: https://cr.minzdrav.gov.ru/recomend/359_2
  2. Padem N., Saltoun C. Classification of asthma. Allergy Asthma Proc. 2019; 40 (6): 385–8. doi: 10.2500/aap.2019.40.4253
  3. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396 (10258): 1204–22. doi: 10.1016/S0140-6736(20)30925-9
  4. Быстрицкая Е.В., Биличенко Т.Н. Обзор общей заболеваемости населения Российской Федерации бронхиальной астмой. Пульмонология. 2022; 32 (5): 651–60 [Bystritskaya E.V., Bilichenko T.N. Review of the general incidence of bronchial asthma in the population of the Russian Federation. Pulmonology. 2022; 32 (5): 651–60 (in Russ.)]. doi: 10.18093/0869-0189-2022-32-5-651-660
  5. World Health Organization. Weekly epidemiological update on COVID-19. 15 July 2024; Edition 169. URL: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---15-july-2024
  6. World Health Organization. Post COVID-19 condition (long COVID), 2022. URL: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition#:text=Definition,months%20with%20no%20other%20explanation
  7. Clinical management of COVID-19: living guideline, 18 August 2023. Geneva: World Health Organization, 2023.
  8. Фассахов Р.С., Визель А.А., Арсланова Л.З. Новая коронавирусная инфекция у больных бронхиальной астмой: первые результаты собственных наблюдений. Практическая пульмонология. 2020; 2: 16–20 [Fassakhov R.S., Wiesel A.A., Arslanova L.Z. A new coronavirus infection in patients with bronchial asthma: the first results of their own observations. Practical pulmonology. 2020; 2: 16–20 (in Russ.)].
  9. Diaz M.A., Catalan-Caceres N., Beauperthuy T.C. et al. Clinical Features and Outcomes Associated with Bronchial Asthma Among COVID-19 Hospitalized Patients. J Asthma Allergy. 2022; 15: 775–81. doi: 10.2147/JAA.S354082
  10. Овсянников Е.С., Авдеев С.Н., Будневский А.В. и др. Бронхиальная астма и COVID-19: вопросы коморбидности. Туберкулез и болезни легких. 2021; 99 (9): 6–14 [Ovsyannikov E.U., Avdeev S.N., Budnevsky A.B. et al. Bronchial asthma and COVID-19: issues of comorbidity. Tuberculosis and Lung Diseases. 2021; 99 (9): 6–14 (in Russ.)]. doi: 10.21292/2075-1230-2021-99-9-6-14
  11. Gonzales-van Horn S.R., Farrar J.D. Interferon at the crossroads of allergy and viral infections. J Leukoc Biol. 2015; 98 (2): 185–94. doi: 10.1189/jlb.3RU0315-099R
  12. Hussein M.H., Elshazli R.M., Attia A.S. et al. Asthma and COVID-19; different entities, same outcome: a meta-analysis of 107,983 patients. J Asthma. 2022; 59 (5): 851–8. doi: 10.1080/02770903.2021
  13. Garcia-Menaya J.M., Cordobés-Durán C., Rangel-Mayoral J.F. et al. Outcomes and Laboratory and Clinical Findings of Asthma and Allergic Patients Admitted With Covid-19 in a Spanish University Hospital. Front Pharmacol. 2020; 11: 570721. doi: 10.3389/fphar.2020.570721
  14. Алекперов Р.И., Макарьянц Н.Н., Чушкин М.И. и др. Особенности течения хронической обструктивной болезни легких у пациентов, перенесших COVID-19. Доктор.Ру. 2024; 23 (1): 7–14 [Alekperov R.I., Makaryants N.N., Chushkin M.I. et al. Features of the course of chronic obstructive pulmonary disease in patients who have undergone COVID-19. Doctor.Ru. 2024; 23 (1): 7–14 (in Russ.)]. doi: 10.31550/1727-2378-2024-23-1-7-14
  15. Абдуллаев Р.Ю., Шорохова В.А., Макарьянц Н.Н. и др. Состояние систем гемостаза и фибринолиза у больных бронхиальной астмой, перенесших инфекцию, вызванную SARS-CoV-2. Сибирское медицинское обозрение. 2024; 2: 50–5 [Abdullaev R.Yu., Shorokhova V.A., Makaryants N.N. et al. The state of hemostasis and fibrinolysis systems in patients with bronchial asthma who have suffered an infection caused by SARS-CoV-2. Siberian Medical Review. 2024; 2: 50–5 (in Russ.)]. doi: 10.20333/25000136-2024-2-50-55
  16. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции. 2022; Версия 15: с. 15–6 [Temporary methodological recommendations. Prevention, diagnosis and treatment of a new coronavirus infection. 2022; Version 15: рр. 15–6 (in Russ.)]. URL: https://minzdrav.gov.ru/ministry/med_covid19

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Frequency of changes in liver functional status indicators in study groups before and after treatment

Download (92KB)
Indexing metadata
3. Fig. 2. Frequency of changes in indicators of lipid metabolism disorders in study groups before and after treatment

Download (75KB)
Indexing metadata
4. Fig. 3. Frequency of shortening of activated partial thromboplastin time and prothrombin time indices in study groups before and after treatment

Download (73KB)
Indexing metadata
5. Fig. 4. Frequency of occurrence of fibrinogen, D-dimer and C-reactive protein elevation in study groups before and after treatment

Download (98KB)
Indexing metadata

Copyright (c) 2025 Russkiy Vrach Publishing House